Skip to search formSkip to main contentSkip to account menu
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
View on PubMed
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
TLDR
Selecting sequential drugs based on the molecular characteristics of a single progressing biopsy is unlikely to provide improved responses, and first-line therapies targeting multiple pathways will be required.
View on Publisher
WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.
TLDR
It is suggested that chronic BRAF inhibition elevates WNT5A expression, which promotes AKT signaling through FZD7 and RYK, leading to increased growth and therapeutic resistance in BRAFi-resistant melanomas.
View on PubMed
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.
TLDR
Analysis of BRAF(V600)-mutant melanoma metastases derived from 10 patients treated with the combination of dabrafenib and trametinib for resistance mechanisms and genetic correlates of response finds the functional differences between these kinases and the preponderance of MEK2 mutations in combination therapy-resistant melanomas.
View on PubMed
Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma
TLDR
The data demonstrate that ctDNA is a useful biomarker of response to kinase inhibitor therapy and can be used to monitor tumor evolution and detect the early appearance of resistance effectors.
View PDF
Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.
TLDR
It is shown that BRAF inhibition suppresses glycolysis via a network of transcription factors that are critical for complete BRAFi responses, and evidence is provided for the clinical potential of therapies that combine BRAFis with glyCOlysis inhibitors.
View on PubMed
IGFBP7 Is Not Required for B-RAF-Induced Melanocyte Senescence
View on Elsevier
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma
  • J. Lee, G. Long, H. Rizos
  • Medicine, Biology
    Annals of oncology : official journal of the…
  • 1 May 2017
TLDR
Longitudinal assessment of ctDNA in metastatic melanoma patients receiving treatment with PD1 inhibitors is an accurate predictor of tumour response, PFS and OS, and this may guide combination and sequencing of subsequent therapies.
View on Wolters Kluwer
Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB
TLDR
Investigation of the mechanism underlying constitutive and inducible expression of programmed death receptor-1 ligand-1 in melanoma cells including cells that had acquired resistance to the BRAF inhibitor vemurafenib suggests selection of treatments that can be used in combination with monoclonal antibodies against PD1 should be considered to enhance their effectiveness and to reduce inhibitory effects melan cancer cells have against cytotoxic T cell activity.
View PDF
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma
TLDR
The efficacy of therapies targeting the MAPK and PI3K/AKT signaling pathways in melanoma is described, the mechanisms contributing to drug resistance are detailed, and current approaches to improving outcomes further are discussed.
View on Wiley
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License